NF-κB-mediated inverse regulation of fractalkine and CX3CR1 during CLP-induced sepsis

Cytokine

Volumn 61, Issue 1, 2013, Pages 97-103

  Raspe C ^a   Hocherl K ^b   Rath, S ^a   Sauvant, C ^a   Bucher, M ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Chemokines; CX3CR1; Fractalkine; NF B; Sepsis

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMOKINE RECEPTOR CX3CR1 GENE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FRACTALKINE GENE; GENE; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; HEART; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEPSIS; TISSUE DISTRIBUTION; TISSUE LEVEL; WESTERN BLOTTING;

ANIMALS; CECUM; CHEMOKINE CX3CL1; DISEASE MODELS, ANIMAL; DOWN-REGULATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIGATION; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; PUNCTURES; PYRROLIDINES; RECEPTORS, CHEMOKINE; RNA, MESSENGER; SEPSIS; THIOCARBAMATES; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84869881030     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.034     Document Type: Article

References (79)

1. Annane D., Bellissant M., Cavaillon J. Septic shock. Lancet 2006, 365:63-78.
2. Angus D.C., Linde-Zwirble J., Lidicker C., Clermont G., Carcillo J., Pinsky M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. Hunter P. Sepsis under siege: a new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO Rep 2006, 7:667-669.
4. Munford R.S., Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001, 163:316-321.
5. Hotchkiss R.S., Karl I. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
6. Monneret G., Lepape A., Voirin N., Bohe J., Venet F., Debard A., et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32:1175-1183.
7. O'Sullivan S., Lederer J., Horgan A., Chin D., Mannick J., Rodrick M. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995, 222:482-490.
8. Asadullah K., Woiciechowsky C., Docke W., Egerer K., Kox K., Vogel S., et al. Very low monocytic HLA-DR expression indicates high risk of infection: immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 1995, 2:184-190.
9. Muehlstedt S., Lyte M., Rodriguez J. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock 2002, 17:443-450.
10. Le Tulzo Y., Pangault C., Amiot L., Guilloux V., Tribut O., Arvieux C., et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 2004, 169:1144-1151.
11. Lekkou A., Karakantza M., Mouzaki A., Kalfarentzos F., Gogos C. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004, 11:161-167.
12. Pachot A., Lepape A., Vey S., Bienvenu J., Mougin B., Monneret G. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 2006, 106:63-71.
13. Foussat A., Coulomb-L'Hermine A., Gosling J., Krzysiek R., Durand-Gasselin I., Schall T., et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000, 30:87-97.
14. Nishimura M., Umehara H., Nakayama M., Yoneda O., Hieshima K., Kakizaki M., et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin_/granzyme B_cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002, 168:6173-6180.
15. Papadopoulos E.J., Fitzhugh D.J., Tkaczyk C., Gilfillan A.M., Sassetti C., Metcalfe D.D. Wang ST. Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur J Immunol 2002, 30:2355-2361.
16. Imai T., Hieshima K., Haskell C.A., Baba M., Nagira M., Nishimura M., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
17. Dichmann S., Herouy Y., Purlis D., Rheinen H., Gebicke-Harter P., Norgauer J. Fractalkine induces chemotaxis and actin polymerisation in human dendritic cells. Inflamm Res 2001, 50:529-533.
18. Schafer A., Schulz C., Eigenthaler M., Fraccarollo D., Kobsar A., Gawaz M., et al. Novel role of the membrane bound chemokine fractalkine in platelet activation and adhesion. Blood 2004, 103:407-412.
19. Hatori K., Nagai A., Heisel R., Ryu J.K., Su K. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 2002, 69:418-426.
20. Maciejewski-Lenoir D., Chen S., Feng L., Maki R., Bacon K.B. Characterisation of fractalkine in rat brain cells: migratory and activation signals for CX3CR1 expressing microglia. J Immunol 1999, 163:1628-1635.
21. Mizuno T., Kawanokuchi J., Numata K., Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 2003, 979:65-70.
22. Ancuta P., Rao R., Moses A., Mehle A., Shaw S.S., Luscinskas W., et al. Fractalkine preferentially mediates arrest and migration of CD16 monocytes. J Exp Med 2003, 197:1701-1707.
23. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1995, 91:521-530.
24. Hundhausen C., Misztela D., Berkhout T., Broadway N., Saftig P., Reiss K., et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003, 102:1186-1195.
25. Garton K., Gough K., Blobel C., Murphy G., Greaves D., Dempsey P., et al. Tumor necrosis factor-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2003, 276:37993-38001.
26. Umehara H., Bloom E., Okazaki T., Nagano Y., Yoshie O., Imai Y. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004, 24:34-40.
27. Fraticelli P., Sironi M., Bianchi G., D'Ambrosio D., Albanesi C., Stoppacciaro A., et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001, 107:1173-1181.
28. Imaizumi T., Yoshida H., Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004, 11:15-21.
29. Fujimoto K., Imaizumi T., Yoshida H., Takanashi S., Okumura K., Satoh K. Interferon-y stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Biol 2001, 25:233-238.
30. Nanki T., Imai T., Nagasaka K., Urasaki Y., Nonomura Y., Taniguchi K., et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:2878-2883.
31. Volin M.V., Woods J.M., Amin M.A., Connors M.A., Harlow L.A., Koch A.E. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001, 159:1521-1530.
32. Combadiere C., Potteaux S., Gao J., Esposito B., Casanova S., Lee E.J., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003, 107:27-34.
33. Greaves D.R., Hakkinen T., Lucas A.D., Liddiard K., Jones E., Quinn C.M., et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymusand activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001, 21:923-929.
34. Cockwell P., Chakravorty S.J., Girdlestone J., Savage C.O. Fractalkine expression in human renal inflammation. J Pathol 2002, 196:85-90.
35. Sukkar M.B., Issa R., Xie S., Oltmanns U., Newton R., Chung K.F. Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. Am J Physiol Lung Cell Mol Physiol 2004, 287(6):1230-1240.
36. Garcia G.E., Xia Y., Chen S., Wang Y., Ye R.D., Harrison J.K., et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000, 7(4):577-584.
37. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
38. Feng L., Chen S., Garcia G., Xia Y., Siani M., Botti P., et al. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int 1999, 56:612-620.
39. Chen S., Bacon K., Li L., Garcia G., Xia Y., Lo D., et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998, 188:193-198.
40. Chen Y., Tu C., Hung K., Wu K., Tsai T., Hsieh B. Inhibition by pentoxifylline of TNF-a-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-κB down-regulation. Br J Pharmacol 2003, 138:950-958.
41. Chakravorty S.J., Cockwell P., Girdlestone J., Brooks C.J., Savage C.O. Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion. Clin Exp Immunol 2002, 129:150-159.
42. Fahy O.L., Coates N.J., McColl S.R. Inhibition of cytokine-induced fractalkine production by bacterial invasion of human-dermal fibroblasts. Lab Invest 2003, 83:721-730.
43. Imaizumi T., Matsumiya T., Fujimoto K., Okamoto K., Cui X., Ohtaki U., et al. Interferon-y stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. Tohoku J Exp Med 2000, 192:127-139.
44. Matsumiya T., Imaizumi T., Fujimoto K., Cui X., Shibata T., Tamo W., et al. Soluble interleukin-6 receptor_inhibits the cytokine-induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 2001, 269:35-41.
45. Muehlhoefer A., Saubermann L.J., Gu X., Luedtke-Heckenkamp K., Xavier R., Blumberg R.S., et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000, 164:3368-3376.
46. Sugaya M., Nakamura M., Mitsui H., Takekoshi T., Saeki H., Tamaki K. Human keratinocytes express fractalkine/CX3CL1. J Dermatol Sci 2003, 31:179-187.
47. Liu S.F., Malik A.B. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol 2006, 290:622-645.
48. Dong L.W., Yang J., Tong L.J. Transcriptional regulation of alpha1-adrenoceptor gene in the rat liver during different phases of sepsis. Biochim Biophys Acta 1999, 1453:207-215.
49. Liu S.F., Ye X., Malik A.B. Inhibition of NFkappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 1999, 100:1330-1337.
50. Liu S.F., Ye X., Malik A.B. In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 1997, 159:3976-3983.
51. Lauzurica P., Martinez-Martinez S., Marazuela M. Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS or TNF-alpha. Eur J Immunol 1999, 29:1890-1900.
52. Albuszies G., Radermacher P., Vogt Effect of increased cardiac output on hepatic and intestinal microcirculatory blood flow, oxygenation, and metabolism in hyperdynamic murine septic shock. Crit Care Med 2005, 33:2332-2338.
53. Teke Z., Aytekin F.O., Aydin C. Effects of pyrrolidine dithiocarbamate on healing of colonic anastomoses in the cecal ligation and puncture model of intraperitoneal sepsis in rats. World J Surg 2007, 31:200-209.
54. Schmidt C., Höcherl K., Kurt B., Moritz S., Kurtz A., Bucher M. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine 2010, 49(1):30-38.
55. Höcherl K., Schmidt C., Kurt B., Bucher M. Inhibition of NF-κB ameliorates sepsis-induced downregulation of aquaporin-2/V2 receptor expression and acute renal failure in vivo. Am J Physiol Renal Physiol 2010, 298(1):196-204.
56. Schmidt C., Kurt B., Höcherl K., Bucher M. Inhibition of NF-kappaB activity prevents downregulation of alpha1-adrenergic receptors and circulatory failure during CLP-induced sepsis. Shock 2009, 32(3):239-246.
57. Schmidt C., Höcherl K., Kurt B., Bucher M. Role of NF-κB dependent induction of cytokines in the regulation of vasopressin V1A receptors during CLP-induced circulatory failure. Crit Care Med 2008, 36(8):1-11.
58. Bucher M., Kees F., Taeger K., Kurtz A. Cytokines downregulate alpha1-adrenergic receptor expression during endotoxemia. Crit Care Med 2003, 31:566-571.
59. Russell J.A. Management of sepsis. N Engl J Med 2006, 355:1699-1713.
60. Holzheimer R., Muhrer K., L'Allemand N., Schmidt T., Henneking K. Intraabdominal infections: classification, mortality, scoring, and pathophysiology. Infection 1999, 19:447-452.
61. Fong A., Robinson L., Steeber D., Tedder T., Yoshie O., Imai T., et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1999, 188:1413-1419.
62. Haskell C., Cleary M., Charo I. Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000, 275:34183-34189.
63. Feezor R., Baker H., Xiao W., Lee W., Huber T., Mindrinos M., et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol 2004, 172:7103-7109.
64. Pachot A., Cazalis M.A., Venet F., Turrel F., Faudot C., Voirin N., et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol 2008, 180(9):6421-6429.
65. He M., Moochhala S.M., Adhikari S., Bhatia M. Administration of exogenous fractalkine, a CX3C chemokine, is capable of modulating inflammatory response in cecal ligation and puncture-induced sepsis. Shock 2009, 31(1):33-39.
66. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.A., et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387:611-617.
67. Beck G., Ludwig F., Schulte J., van Ackern K., van der Woude F.J., Yard B.A. Fractalkine is not a major chemoattractant for the migration of neutrophils across microvascular endothelium. Scand J Immunol 2003, 58:180-187.
68. Sung M.J., Kim W., Ahn S.Y., Cho C.H., Koh G.Y., Moon S.O., et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res 2005, 97:880-890.
69. Wang L., Li T.Q., Xiang G.X., Wang G. Effect of dexamethasone on expression of fractalkine in lipopolysaccharide-induced acute lung injury. Sichuan Da Xue Xue Bao Yi Xue Ban 2006, 37(2):250-253.
70. Bhavsar P.K., Sukkar M.B., Khorasani N., Lee K.Y., Chung K.F. Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J 2008, 22(6):1807-1816.
71. Ishida Y., Hayashi T., Goto T., Kimura A., Akimoto S., Mukaida N., et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol 2008, 181(6):4208-4218.
72. Guo X., Pan Y., Xiao C., Wu Y., Cai D., Gu J. Fractalkine stimulates cell growth and increases its expression via NF-κB pathway in RA-FLS. Int J Rheum Dis 2012, 15(3):322-329. Epub 2012 Feb 28. 10.1111/j.1756-185X.2012.01721.x.
73. Fang I.M., Lin C.P., Yang C.M., Chen M.S., Yang C.H. Expression of CX3C chemokine, fractalkine, and its receptor CX3CR1 in experimental autoimmune anterior uveitis. Mol Vis 2005, 1(11):443-451.
74. Huang L.Y., Chen P., Xu L.X., Zhou Y.F., Zhang Y.P., Yuan Y.Z. Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model. Inflammation 2012, 35(3):1023-1030.
75. Cummings C., Martin T., Frevert C., Quan C., Wong V., Mongovin S., et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999, 162:2341-2346.
76. Heesen M., Renckens R., de Vos A., Kunz D. Human endotoxemia induces down-regulation of monocyte CC chemokine receptor 2. Clin Vaccine Immunol 2006, 13:156-159.
77. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novart Fdn Symp 2007, 280:21-27.
78. Nishiya T., Uehara T., Edamatsu H., Kaziro Y., Itoh H., Nomura Y. Actibation of Stat1 and subsequent transcription of inducible nitric oxide synthase gene in c6 glioma cells is independent of interferon-gamma-induced MAPK activation that is mediated by p21ras. FEBS Lett 1997, 408:33-38.
79. Gonin S., Peijnenburg A., Keijsers V., van Elsen P. Site alpha is crucial fort wo routes of IFN-gamma induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 1997, 6:601-611.